After bone marrow transplantation (BMT), a prolonged dysregulation of humoral immunity can be observed. In the present study, we investigated whether this is reflected in an abnormal production of specific antibodies (Ab) t o the Tcell-dependent recall antigen tetanus-toxoid (TT). The study group consisted of children receiving transplants of an unmodified allogeneic graft and of adults receiving either a Tcell-depleted allogeneic or an unmodified autologous BM graft. Findings were compared with those in healthy controls. In pediatric graft recipients, who were routinely revaccinated early after BMT, the Ab response was quantitatively superior to that in adult graft recipients who did not receive early revaccination. In the majority of graft recipients, the time period after vaccination required t o reach the peak level of antibodies was prolonged and the number of responding TT-specific B-cell clones was markedly decreased in comparison with controls. In controls, a low frequency of dominant ONE MARROW transplant (BMT) recipients may suffer from an immunologic deficiency up to several years after transplant.' In the absence of chronic graft-versus-host disease (GVHD), normalization of B-cell function is considered to take place within 1 to 2 years.' Although B-cell numbers become normal at 4 to 8 months posttransplant, their phenotype is immature and their function is inadequate in a way similar to that found during ~ntogeny.'.~ Transient Ig (sub)class deficiencies may be observed after BMT.'" In addition, Ig synthesis is clonally dysregulated for some time after transplantation, resulting in monoclonal gammopathies (MG) and restricted heterogeneity of Ig.7.x An abnormal humoral immune response may thus persist despite a normalization of serum Ig (sub)class levels. Specific antibody (Ab) production can be detected from 3 months after BMT onwards, depending on the vaccines used"" and on whether the donors or the recipients had been vaccinated before BMT.I4-IX However, detailed information on qualitative aspects of the Ab response in BMT recipients is still lacking.
B-cell clones may produce low quantities of homogeneous Ab components (H-Ab) against a heterogeneous background. However, in BM graft recipients, "overshooting" of Ab production by separate B-cell clones was observed, resulting in the development of H-Ab at a relatively high concentration. These abnormalities were present up t o 10 years after BMT, irrespective of either the age of the recipient, the modulation of the graft, or the vaccination schedule used. It is hypothesized that the dysregulated Ab production is the consequence of activation of a restricted number of resting memory B cells, present in germinal centers, repopulating gradually after BMT. Our data show that routine revaccination early after BMT improves the humoral immune response. However, because of a clonally dysregulated Ab production, long-lasting qualitative defects may be present even after normalization of Ab titers. anti-TT response, as assessed by the electrophoretic heterogeneity of TT-specific IgG antibodies in sera from children and adults vaccinated after BMT. The findings were compared with those found in routinely vaccinated healthy infants, children, and adults. Although normal Ab titers were already reached at 4 months after BMT in the majority of recipients, the number of B-cell clones involved in the response was markedly reduced for a prolonged period of time. Sometimes the response was largely dominated by a single clone and seemingly monoclonal. These abnormalities could be found as long as 10 years after BMT.
MATERIALS AND METHODS

Controls and Patients
This study was approved by the Institutional Review Boards on Medical Ethics at the University Hospital (BMT center for children), Leiden, The Netherlands and the Dr. Daniel den Hoed Cancer Center (BMT center for adults), Rotterdam, The Netherlands.
Controls
Sera from 20 healthy infants and children, observed from birth up to the age of 4 years, and from 20 healthy adult volunteers with a median age of 35 years (range, 25 to 45 years) were used as controls.
Pediutric Patients
Children receiving grafts of BM cells from an HLA-identical sibling between 1982 and 1989, who were cured of their original disease and who are alive and well, were included in the study (n = 38). The characteristics of these patients are given in Table 1 . All received an unmodified BM graft while staying in the protective environment of a laminar flow isolator and after antimicrobial suppression of their intestinal micro-flora." By January I , 1993, the median follow-up after BMT was 7.5 years (range, 1 .0 to 1 1 .0 years). As we previously reported, complete chimerism was present in the majority of patients.20
Adult Patients
Recipients treated with either an HLA-identical sibling graft (n = 26) or an autologous graft (n = 9) between 1980 and 1992 who Abbreviations: AML, acute myeloblastic leukemia in first ( n = 30) or second (n = 1) remission; ALL, acute lymphoblastic leukemia in first ( n = 6 ) or second ( n = 13) remission; NHL, non-Hodgkin's lymphoma; CML, adult (Ph') chronic myeloblastic leukemia; Others, for children, severe aplastic anaemia (n = 2). @-thalassemia maior (n = 2), and combined immunodeficiency (n = l), for adults, M. Hodgkin (n = 2), multiple myeloma (n = 2), paroxysmal nocturnal hemoglobinuria (PNH; n = l), and mamma carcinoma (n = 1); CTX 120-200, cyclophosphamide 2 x 60 or 4 x 50 mg/kg; TB1 7-12, total body irradiation in grays (Gy), dose depending on age of recipient administered in one ( 5 8 Gy) or 2 (210 Gy) fractions with a dose rate of 24 to 48 cGy/min; 61.116, busulphan for 4 days at 4 mg/kg; GVHD, graft-versushost disease; TCD, r2 log T-cell depletion; MTX, methotrexate <50 mg/m2 in only first 2 weeks (n = 20). >l00 mg/m2 until day +l00 (n = 14; children with MTX only); CSA, cyclosporin A 2 mg/kg intravenously or 6 mg/kg orally for at least 3 months after BMT.
In 13 patients, MTX and/or cyclosporin A was administered in addition to TCD.
Graft
GVHD prophylaxis
Acute GVHD Chronic GVHD were alive and well were included. The characteristics of these patients are given in Table l . In case of an allogeneic BMT, the graft was more than 2 log T-cell-depleted by albumin gradient centrifugation and E rosette sedimentation?' By January 1, 1993, the median follow-up of these patients was 2.5 years (range, 0.5 to 13.0 years).
Methods
Vaccination
Controls. Twenty healthy infants and children were vaccinated according to the Dutch National Vaccination Program with diphtheria toxoid (D)-pertussis (P)-tetanus toxoid (T)-inactivated polio virus type I, 11, and 111 (IPV) at 3, 4, 5, and 11 (n = 16) or at 14 (n = 4) months (DPT-IPV I to IV) and with DT-IPV at 4 and 9 years of age (DT-IPV V and VI; Table 2 ). In addition, 20 healthy adult volunteers received a DT-IPV booster (B) vaccination.
Pediatric patients. The patients and their BM donors had been vaccinated during infancy and early childhood with D(P)T-IPV vaccine, according to the Dutch National Vaccination Program. Twentyseven of 38 patients were immunized with DT-IPV within l month before BMT (DT-IPV 0; Table 2 ). In the light of other studies,"." 5 BM donors also received a DT-IPV vaccination within 2 weeks before graft donation.
In the first 4 months after BMT, the recipients received 3 DT-IPV booster injections (I to 111) with an interval of 1 month, starting from 6 weeks after BMT. A limited number of children received an additional injection (IV) between 6 and 24 months after BMT. In 1992, 21 children with a follow-up period of at least 3 years (range, 3 to 10 years) after BMT again received a DT-IPV injection (DTAdult patients. As far as could be evaluated, all adult BM graft recipients and their donors had received routine D(P)T-IPV vaccinations in infancy and childhood. In addition, most male patients had received a DT-IPV injection at the start of their military service. None of the adult patients was vaccinated shortly before BMT and none received revaccination after BMT until the occurrence of an outbreak of poliomyelitis in The Netherlands (November 1992). At that time, all patients received three DT-IPV vaccinations at monthly intervals and one vaccination 6 months later. The response to the second vaccination (DT-IPV 11) was investigated.
IPV V).
Serum Samples
Serum samples were obtained after informed consent before and at a median of 3 weeks (range, 2 to 4 weeks) after vaccination, with the following exceptions. From children of the control group receiving DPT-IPV IV at 14 months of age (n = 4), the postvaccination serum sample was taken 4 weeks later; from those immunized at 11 months of age (n = 16), serum was taken at 4 months after vaccination. Cord blood samples were available from all healthy infants included in the study. Sera from healthy adults were obtained at 2 and 4 weeks and at 3, 6, and 12 months after the booster. From pediatric graft recipients, serum samples were also obtained at 3 and 6 months after DT-IPV IV. From adult graft recipients, only one serum sample, taken 4 weeks after the second DT-IPV vaccination, was available. All sera were kept frozen at -20°C until analysis.
Serum Analysis
Quantification of IgG anti-7T antibodies. The concentration of IgG anti-TT antibodies was measured by enzyme-linked immunosorbent assay (ELISA), as has previously been described.** The concentration was expressed in arbitrary units (AU) per milliliter using a reference serum for standardization. The Ab response in healthy children after DT-IPV VI at 9 years of age was not investigated in this study. Data on IgG anti-'M levels after vaccination of 8 pediatric graft recipients early after BMT were not included, because the children were being treated at that time for acute or chronic GVHD with immunosuppressive therapy.
Dejinition of response to TT. In healthy infants (controls), a primary Ab response to 'M was scored as positive if the postimmunization IgG titer was at least twice the preimmunization titer and reached 20.2 AU/mL. In pediatric and adult controls and in the pediatric patients a secondary Ab response was considered positive in case of an increase of the post-immunization IgG titer to 125% of the pre-immunization titer, reaching at least 1.0 AU/mL. In two cases, newly arising TT-specific homogeneous Ab components (HAb) were detected in the absence of an increase of the Ab titer. This finding was interpreted as an indication for a positive TT response.
I n the adult patients. a preimmunization sample was not available.
In these patients, an
A b response was defined as positive if the postimmunization titer was 2 1.0 AUlmL. The titer values were analysed using the Student's f-test.
RESULTS
Quantification of IgG Anti-TT Antibodies
Controls. After the first vaccination, 45% of the infants responded to TT (Table 3 ). The infants who responded had a lower preimmunization Ab titer in the cord blood and in the prevaccination sample than did the nonresponders ( P < response after booster vaccination. The geometric mean of the Ab titers (GMT) was highest in children at 4 years of age and lowest in infants at 12 months of age.
Pediatric patients. In none of the 4 patients who received a vaccination within 2 days before the start of the conditioning regimen for BMT was an Ab response observed. Seventy percent of the other evaluable patients (n = 23) responded to vaccination before BMT (Table 3) . irrespective of the prevaccination titer and even when vaccinated as little as S days before the start of the conditioning regimen. The GMT in responders was much lower than in control infants and children, probably as a result of preceding antileukemic treatment.
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After the first vaccination, at 7 weeks after BMT, 30% of the pediatric recipients responded. There was no statistically significant difference between responders and nonresponders with respect to prevaccination Ab titers, substitution with gammaglobulins, or treatment with cyclosporin A. Two revaccinations at I 1 and 15 weeks after BMT resulted in a cumulative response rate of 75% of the graft recipients. Although this finding was not investigated systematically. we observed that the maximum Ab titer was reached at 4 weeks or even later after immunization and not at 2 weeks as in adult controls after booster vaccination.
Revaccination between 6 and 24 months after BMT resulted in a IO0% response rate and a significantly increased GMT (Table 3 ). There was no difference between patients with (n = 6) or without (n = 17) preceding acute GVHD. Booster vaccination at 3 to I O years after RMT resulted in a 100% response rate and a GMT similar to that in controls. Follow-up investigations showed a half-life of Ab titers comparable to that in adult controls (data not shown).
Addt patients. There were no significant differences with respect to the percentage of responders between adult patients who received a TCD allogeneic graft (14 of 26) and those who received an autologous graft (4 of 9), nor was there a difference between patients vaccinated 0.5 to 2 years (6 of 17) and those vaccinated more than 2 years after BMT (12 of 18). Also, the GMT was not different between these subgroups. Ten adult patients (about 30%) had an IgG anti-TT titer after two DT-IPV immunizations that may not have been protective. ie, less than 0.1 AU/mL.
Heterogeneity and Oligoclonnlity qf IgC Anti-TT
Controls.
TT-specific H-Ab were hardly detectable in cord blood and sera of infants after four DPT-IPV vaccinations (Fig 3A) . After revaccination at 4 years of age or in adulthood, either one or two TT-specific H-Ab of low concentration (<0.1 pg/mL) could be observed in serum samples of about 35% of the controls, on top of an overall heterogeneous Ab response ( Figs 2B and 3A) .
BMT patients. TT-specific H-Ab of low concentration could be observed in preimmunization serum samples of about 25% of the pediatric patients before BMT (Fig 3B) . After pre-BMT vaccination, this percentage was SO%, which was not significantly different from healthy children at the age of 4 years and from adults. However, after the first and second post-BMT vaccination, it increased significantly to 75% and 10096, respectively. In addition, the number of HAb per serum sample and the quantity of some H-Ab increased ( Figs 2C and D and 3B) .
After booster vaccination in the second half year after BMT, H-Ab at a medium and high concentration were found in about SO% of the patients. At follow-up investigation, 3 to I O years after BMT, 7S% of the patients still had H-Ab in their serum. In some cases, these H-Ab were of relatively high concentration, ie, greater than 1 .O pdmL (Figs 2D and  3B) .
In about 30% of the adult graft recipients who responded to TT vaccination, the postimmunization serum showed HAb. These H-Ab were also frequently at a relatively high concentration. In general, there was a strong correlation between the presence and concentration of H-Ab and the quan- tity of IgG anti-TT in postvaccination sera of BMT recipients. Combination of the quantitative and qualitative data indicates that 40% of the sera with IgG anti-TT levels less than 20 AU/mL contained H-Ab, 20% of which were of medium or high concentration. H-Ab were present in 70% of the sera with IgG anti-TT levels greater than 20 AU/mL; 60% of these H-Ab were at a medium or high concentration. In 7 pediatric graft recipients with H-Ab at a high concentration in the first year after BMT, WABL and FABL showed that, at 3 to 10 years after BMT, 2 graft recipients had a heterogeneous Ab response and 3 had a restricted pattern with H-Ab produced by the original B-cell clone(s) (Fig 4) . The other 2 cases showed, in addition to H-Ab produced by the original B-cell clone, H-Ab at a high concentration produced by new clones, obviously triggered by revaccination.
Response to D(P)T-IPV
DISCUSSION
Our previous study on the recovery of serum Ig isotypes and the occurrence of MG after BMT' was extended here to investigate the quantity and quality, in terms of electrophoretic heterogeneity, of the specific IgG Ab formation after vaccination with the T-cell-dependent TT antigen.
In accordance with previous reports,"1o we found a quantitatively decreased Ab production in recipients of a BM graft early after BMT in comparison with the response on a booster vaccination in healthy controls (but not in comparison with infants who received the first course of 3 vaccinations). IgG antibodies to TT are produced by memory B cells with the help of T cells. Early after BMT, the number of memory B cells may be low. It has also been shown that the number of T-helper cells and precursors is low.26 In addition, the production of and response to interleukin-2 (IL-2) is de~reased~'.'~ and this has a detrimental effect on the proliferative response after stimulation of T cells via the Tcell receptor-CD3 complex by antigens and anti-CD3.28,2' Therefore, it seems paradoxical that specific Ab production to recall antigens in BMT recipients precedes normalization of in vitro T-cell responses by a number of months.' This finding is in contrast to the finding of a relatively high number of CD4' CD45RO' T lymphocytes in peripheral blood after BMT,30 unless this population belongs to the TH2 subcenters of BMT recipients may be activated by other as yet unknown mechanisms. It is attractive to speculate that alloantigens may be involved in this activation. B cells may interact with activated T cells in a major histocompatibility complex (MHC)-unrestricted and antigen nonspecific way set.31"2 and proliferate and mature to Ig-producing cells in the presence of interleukins (ie, IL-4 and IL-10).31"4 Interestingly, Ig levels in graft recipients with acute GVHD are significantly higher than in recipients witho~t.~'
Alternatively, the majority of T cells in the germinal
In the present study, we showed that the occurrence of HAb at a low concentration within an otherwise heterogeneous response is a normal phenomenon, because this type of clonal dominance was also found in healthy children after DT-IPV V and in adult controls after booster vaccination. Clonal dominance has also been described in adults after influenza vaccination.36 However, in BM graft recipients, the restricted heterogeneity of TT-specific IgG and the development of H-Ab at a relatively high concentration has to be considered as an abnormal response. This oligoclonal Ab response was found both in children receiving grafts of unmodified BM and vaccinated before and early after BMT and in adults receiving grafts of either autologous or T-celldepleted allogeneic BM who did not receive revaccination early after BMT. Previous studies in immune-deficient mice and in Rhesus monkeys after BMT also showed a similar r e s p o n~e .~~.~' There are at least two possible explanations for this restricted response of prolonged duration. First, it may be the result of the transfer of a limited number of memory B-cell clones from the donor. This hypothesis is in accordance with the finding of a skewed Ig VH repertoire of B cells early after BMT.39 Under certain conditions, booster vaccination of the BM donor 2 weeks before donation has been shown to increase the quantitative Ab response in the recipient^.'^"'"^ On careful observation of the data presented in some of those it can be concluded that this response was also oligoclonal. Second, it may be that only a limited number of memory B cells become activated in view of the restricted possibilities for cell-cell contact with T-helper cells, resulting from underrepresentation of the latter population in germinal centers after BMT. Results of animal experiments are in favor of the latter hypothesis because restricted heterogeneity of Ig and H-Ig develop after thymectomy and disappear again after infusion of peripheral T ~e l l s . 4 '~~~ However, the persistence of a restricted Ab response and of H-Ab of high concentration in a number of graft recipients many years after BMT, when numbers and functions of specific T cells have become normal,' indicates that, in addition to abnormalities at the T-cell level, abnormalities at the B-cell level may persist. In murine graft recipients, germinal center reconstitution after BMT has been shown to be oligoclonal after antigenic stimulation? In human BMT, a delayed reconstitution of germinal centers has been described in cases with GVHD. 44 Our findings of an impaired specific Ab response post-BMT have clinical implications with respect to vaccination policy of BMT recipients. Previous studies showed longlasting but transient persistence of donor immunity in nonvaccinated BMT recipient^.^^.^"^^ Vaccination of the donor before graft donation, together with vaccination of the recipient early after BMT, may contribute to a quantitatively good Ab response. BM graft recipients respond to vaccinations in the following sequence: TD-recall antigens (at about 3+ months), TD-primary antigens (at about 6+ months), and Tcell-independent antigens (at about l + year).' This sequence can be observed after BMT with either an unmodified graft,' a T-cell-depleted graft,I5.l6 or a B-cell depleted graft.47,48 However, under the latter condition, all responses are primary because of the lack of transferred memory Bcell clones.47 In the present study, we showed that repeated vaccinations of children early after BMT resulted in a quantitatively enhanced specific humoral immunity at 6 to 24 months after BMT, whereas this response in adults was not yet normal at 2 years post-BMT after two vaccinations. However, we do not know whether the qualitative abnormalities, present as a clonally restricted response, will provide adequate protection. It may be that increased quantity compensates for decreased quality of antibodies in the first years after BMT.
With our very sensitive technique we have clearly shown long-lasting oligoclonality at the B-cell level after BMT. Preliminary data on the T-cell receptor repertoire, which is of relevance for antigen-specific help for B cells, do not indicate a long-lasting oligoclonality at the T-cell level4'
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